The Patent Finder

Terms ending in 2029

Pharma Cinq, LLC

Every in-force patent on Pharma Cinq, LLC's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,115,072Compounds and Method for Reducing Uric Acid
In force (reinstated)
 · High confidence
Pharma Cinq, LLCIn force (reinstated)High confidence
US 8,178,675Compounds for the Treatment of Metabolic Disorders
In force
 · High confidence
Pharma Cinq, LLCIn forceHigh confidence
US 8,889,724Tetrazole Compounds for Reducing Uric Acid
In force
 · High confidence
Pharma Cinq, LLCIn forceHigh confidence
US 8,557,531Detection of Circulating Endothelial Cells
In force
 · High confidence
Pharma Cinq, LLCIn forceHigh confidence
US 8,481,595Compounds for the Treatment of Metabolic Disorders
In force
 · High confidence
Pharma Cinq, LLCIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited